Back to Search Start Over

Estrogen reverses nicotine‐induced inflammation in chondrocytes via reducing the degradation of ECM

Authors :
Zhiguang Qiao
Xiaoyun Peng
Zhongdong Qiao
Yilin Xie
You Wang
Zhaoxia Wang
Huiqin Li
Mei Xin
Source :
International Journal of Rheumatic Diseases. 22:666-676
Publication Year :
2019
Publisher :
Wiley, 2019.

Abstract

Problem Osteoarthritis (OA) is a chronic disease with a very high incidence and the pathology of which is quite complex. Epidemiological investigation showed that OA may be related to smoking and estrogen levels, but there are few studies focused on the cross-effect of these two factors. This research aims to investigate the molecular mechanism of nicotine and estrogen effects on chondrocytes to study the effect of smoking on the incidence of osteoarthritis in women. Method of the study Nicotine was added to obtain inflammatory supernatants of macrophages, which were used to induce chondrocyte inflammation. Toluidine staining and immunohistochemistry were used to detect the extracellular matrix (ECM) of chondrocytes, while the important proteins in the metabolism of chondrocytes were detected by Western blot. Results Nicotine-induced inflammatory supernatant promoted the degradation of ECM, such as type II collagen, aggrecan and proteoglycan 4. While in the presence of physiological concentrations of estrogen, this destructive effect is reversed. On the molecular level, estrogen (17β-estradiol, 1 nmol/L) can inhibit the matrix degrading enzymes and promote the transforming growth factor (TGF)-β1 pathway which is involved in matrix synthesis. However, in the presence of inflammatory induction, although estrogen could still inhibit the expression of matrix degrading enzymes, it inhibited the TGF-β1 pathway. Moreover, the different inflammatory factors in the inflammatory supernatant, mainly tumor necrosis factor-α, interleukin-1β, had different effects on the metabolic processes of chondrocytes. Conclusion Estrogen reverses nicotine-induced inflammation mainly via reducing the degradation of ECM. The cross-effect of estrogen and inflammatory factor inhibitors can be a potential clinical reference for OA patients.

Details

ISSN :
1756185X and 17561841
Volume :
22
Database :
OpenAIRE
Journal :
International Journal of Rheumatic Diseases
Accession number :
edsair.doi.dedup.....5ec282d5a8f64c588b673d84a5fe43a7